Future Development

 

ECT is a unique and versatile platform with the ability to continuously produce and deliver targeted therapeutics both singly or in combination, to the back of the eye long-term with no immunologic effect. Recombinant cell lines derived from transfected NTC-200 cells are able to secrete major classes of therapeutics, including antibodies, fusion proteins, and growth factors, potentially enabling the ECT platform treat a broad array of chronic ocular diseases.

 

Neurotech © 2016

News Update

Find out the latest news at Neurotech